Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b

doi:10.1016/j.ijantimicag.2020.106052

Case Reports

. 2020 Aug;56(2):106052.

doi: 10.1016/j.ijantimicag.2020.106052. Epub 2020 Jun 13.

Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b

Sun In Hong¹, Byung-Han Ryu¹, Yong Pil Chong², Seungjun Lee³, Sunjoo Kim³, Ho Cheol Kim⁴, Kyung-Wook Hong⁵, In-Gyu Bae⁶, Oh-Hyun Cho⁷

Affiliations

¹ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea.
² Division of Infectious Diseases, Department of Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
³ Department of Laboratory Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea.
⁴ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁵ Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁶ Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁷ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea. Electronic address: zenmd@naver.com.

PMID: 32544570
PMCID: PMC7293467
DOI: 10.1016/j.ijantimicag.2020.106052

Case Reports

Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b

Sun In Hong et al. Int J Antimicrob Agents. 2020 Aug.

. 2020 Aug;56(2):106052.

doi: 10.1016/j.ijantimicag.2020.106052. Epub 2020 Jun 13.

Authors

Sun In Hong¹, Byung-Han Ryu¹, Yong Pil Chong², Seungjun Lee³, Sunjoo Kim³, Ho Cheol Kim⁴, Kyung-Wook Hong⁵, In-Gyu Bae⁶, Oh-Hyun Cho⁷

Affiliations

¹ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea.
² Division of Infectious Diseases, Department of Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
³ Department of Laboratory Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea.
⁴ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁵ Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁶ Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁷ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea. Electronic address: zenmd@naver.com.

PMID: 32544570
PMCID: PMC7293467
DOI: 10.1016/j.ijantimicag.2020.106052

No abstract available

Keywords: COVID-19; Coronavirus; Hydroxychloroquine; Interferon; Lopinavir/ritonavir; SARS-CoV-2.

PubMed Disclaimer

Figures

**Fig. 1**
Clinical characteristics for individual patients included in the case series.

See this image and copyright information in PMC

Cited by

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.
Vinh DC, Abel L, Bastard P, Cheng MP, Condino-Neto A, Gregersen PK, Haerynck F, Cicalese MP, Hagin D, Soler-Palacín P, Planas AM, Pujol A, Notarangelo LD, Zhang Q, Su HC, Casanova JL, Meyts I; COVID Human Genetic Effort. Vinh DC, et al. J Clin Immunol. 2021 Oct;41(7):1425-1442. doi: 10.1007/s10875-021-01068-6. Epub 2021 Jun 8. J Clin Immunol. 2021. PMID: 34101091 Free PMC article. No abstract available.
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial.
Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, Fazeli MR, Ghazaeian M, Yekaninejad MS. Rahmani H, et al. Int Immunopharmacol. 2020 Nov;88:106903. doi: 10.1016/j.intimp.2020.106903. Epub 2020 Aug 24. Int Immunopharmacol. 2020. PMID: 32862111 Free PMC article. Clinical Trial.
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
Ashour NA, Abo Elmaaty A, Sarhan AA, Elkaeed EB, Moussa AM, Erfan IA, Al-Karmalawy AA. Ashour NA, et al. Drug Des Devel Ther. 2022 Mar 15;16:685-715. doi: 10.2147/DDDT.S354841. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35321497 Free PMC article.
Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.
Heustess AM, Allard MA, Thompson DK, Fasinu PS. Heustess AM, et al. Pharmaceuticals (Basel). 2021 May 28;14(6):520. doi: 10.3390/ph14060520. Pharmaceuticals (Basel). 2021. PMID: 34071185 Free PMC article. Review.
Mutant strains of SARS-CoV-2 are more prone to infect obese patient: a review.
Ningombam SS, Kumar R, Tanwar P. Ningombam SS, et al. Wien Klin Wochenschr. 2021 Apr;133(7-8):383-392. doi: 10.1007/s00508-021-01819-w. Epub 2021 Feb 17. Wien Klin Wochenschr. 2021. PMID: 33595720 Free PMC article. Review.

See all "Cited by" articles

References

1. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re...]
1. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402. doi: 10.1016/S1473-3099(20)30132-8. - DOI - PMC - PubMed
1. Arashiro T, Furukawa K, Nakamura A. COVID-19 in 2 Persons with Mild Upper Respiratory Tract Symptoms on a Cruise Ship, Japan. Emerg Infect Dis. Jun 2020;26:1345–1348. doi: 10.3201/eid2606.200452. - DOI - PMC - PubMed
1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Mar 13 2020 doi: 10.1001/jamainternmed.2020.0994. [Epub ahead of print] - DOI - PMC - PubMed
1. Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early Short Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. May 19 2020 doi: 10.1093/cid/ciaa601. [Epub ahead of print] - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re...]

[2] WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re...]

[3] Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402. doi: 10.1016/S1473-3099(20)30132-8. - DOI - PMC - PubMed

[4] Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402. doi: 10.1016/S1473-3099(20)30132-8. - DOI - PMC - PubMed

[5] Arashiro T, Furukawa K, Nakamura A. COVID-19 in 2 Persons with Mild Upper Respiratory Tract Symptoms on a Cruise Ship, Japan. Emerg Infect Dis. Jun 2020;26:1345–1348. doi: 10.3201/eid2606.200452. - DOI - PMC - PubMed

[6] Arashiro T, Furukawa K, Nakamura A. COVID-19 in 2 Persons with Mild Upper Respiratory Tract Symptoms on a Cruise Ship, Japan. Emerg Infect Dis. Jun 2020;26:1345–1348. doi: 10.3201/eid2606.200452. - DOI - PMC - PubMed

[7] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Mar 13 2020 doi: 10.1001/jamainternmed.2020.0994. [Epub ahead of print] - DOI - PMC - PubMed

[8] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Mar 13 2020 doi: 10.1001/jamainternmed.2020.0994. [Epub ahead of print] - DOI - PMC - PubMed

[9] Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early Short Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. May 19 2020 doi: 10.1093/cid/ciaa601. [Epub ahead of print] - DOI - PMC - PubMed

[10] Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early Short Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. May 19 2020 doi: 10.1093/cid/ciaa601. [Epub ahead of print] - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b

Affiliations

Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b

Authors

Affiliations

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous